HK1213889A1 - 殼氨醯胺酶抑制劑及使用方法 - Google Patents

殼氨醯胺酶抑制劑及使用方法

Info

Publication number
HK1213889A1
HK1213889A1 HK16101849.3A HK16101849A HK1213889A1 HK 1213889 A1 HK1213889 A1 HK 1213889A1 HK 16101849 A HK16101849 A HK 16101849A HK 1213889 A1 HK1213889 A1 HK 1213889A1
Authority
HK
Hong Kong
Prior art keywords
glutaminase inhibitors
glutaminase
inhibitors
Prior art date
Application number
HK16101849.3A
Other languages
English (en)
Inventor
.勒米厄
.泊泊威次-馬勒
.薩利圖如
.撒德斯
.特維斯
顏順启
Original Assignee
Agios Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agios Pharmaceuticals Inc filed Critical Agios Pharmaceuticals Inc
Publication of HK1213889A1 publication Critical patent/HK1213889A1/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D285/00Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01Five-membered rings
    • C07D285/02Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/121,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/1251,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/135Nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D285/00Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01Five-membered rings
    • C07D285/02Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/121,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
HK16101849.3A 2012-11-21 2016-02-18 殼氨醯胺酶抑制劑及使用方法 HK1213889A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261729321P 2012-11-21 2012-11-21
PCT/US2013/071212 WO2014081925A1 (en) 2012-11-21 2013-11-21 Glutamase inhibitors and method of use

Publications (1)

Publication Number Publication Date
HK1213889A1 true HK1213889A1 (zh) 2016-07-15

Family

ID=49780330

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16101849.3A HK1213889A1 (zh) 2012-11-21 2016-02-18 殼氨醯胺酶抑制劑及使用方法

Country Status (15)

Country Link
US (3) US9303002B2 (zh)
EP (1) EP2922832B1 (zh)
JP (1) JP6333280B2 (zh)
KR (1) KR20150085078A (zh)
CN (1) CN105263915B (zh)
AU (2) AU2013347933C1 (zh)
BR (1) BR112015011756A2 (zh)
CA (1) CA2892089A1 (zh)
EA (1) EA029531B1 (zh)
ES (1) ES2761951T3 (zh)
HK (1) HK1213889A1 (zh)
IL (1) IL238959A (zh)
MX (1) MX369691B (zh)
SG (1) SG11201504022RA (zh)
WO (1) WO2014081925A1 (zh)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011323524B2 (en) 2010-11-01 2016-12-08 Eyepoint Pharmaceuticals Us, Inc. Bioerodible silicon-based devices for delivery of therapeutic agents
US8604016B2 (en) 2011-11-21 2013-12-10 Calithera Biosciences Inc. Heterocyclic inhibitors of glutaminase
EA029707B1 (ru) 2012-11-16 2018-05-31 Калитера Байосайенсиз, Инк. Гетероциклические ингибиторы глютаминазы
BR112015011756A2 (pt) 2012-11-21 2017-07-11 Agios Pharmaceuticals Inc inibidores da glutamase e métodos de uso
WO2014079011A1 (en) 2012-11-22 2014-05-30 Agios Pharmaceuticals, Inc. Heterocyclic compounds for inhibiting glutaminase and their methods of use
EA201991183A1 (ru) 2014-01-06 2020-02-28 Ризен Фармасьютикалз Са Новые ингибиторы глутаминазы
CN106231900B (zh) 2014-03-21 2019-05-28 阿吉奥斯制药公司 化合物及其使用方法
CA2947130C (en) 2014-04-30 2018-10-02 Pfizer Inc. Cycloalkyl-linked diheterocycle derivatives
GB201409624D0 (en) 2014-05-30 2014-07-16 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer
AU2015274361B2 (en) 2014-06-13 2020-11-05 Calithera Biosciences, Inc. Combination therapy with glutaminase inhibitors
CA2953989C (en) 2014-07-03 2023-10-10 Board Of Regents, The University Of Texas System Gls1 inhibitors for treating disease
WO2016007647A1 (en) 2014-07-09 2016-01-14 The Johns Hopkins University Glutaminase inhibitor discovery and nanoparticle-enhanced delivery for cancer therapy
WO2016014890A1 (en) * 2014-07-24 2016-01-28 Calithera Biosciences, Inc. Treatment of multiple myeloma with heterocyclic inhibitors of glutaminase
WO2016022465A1 (en) * 2014-08-04 2016-02-11 Drexel University Novel compounds and methods of treating or ameliorating an il-1r-mediated disease or disorder using same
EA037738B1 (ru) 2014-08-07 2021-05-17 Калитера Байосайенсиз, Инк. Кристаллические формы ингибиторов глутаминазы
KR20170131650A (ko) * 2015-03-30 2017-11-29 칼리테라 바이오사이언시즈, 인코포레이티드 글루타미나제 억제제의 투여 방법
CN107949387B (zh) 2015-04-06 2021-08-13 卡利泰拉生物科技公司 用谷氨酰胺酶抑制剂治疗肺癌
US10125128B2 (en) 2015-06-30 2018-11-13 Board Of Regents, The University Of Texas System GLS1 inhibitors for treating disease
CN108601767A (zh) 2015-10-05 2018-09-28 卡利泰拉生物科技公司 用谷氨酰胺酶抑制剂和免疫肿瘤学药剂的组合疗法
EP3394039A4 (en) 2015-12-22 2019-06-12 Board of Regents, The University of Texas System SALT FORMS AND POLYMORPHS OF (R) -1- (4- (6- (2- (4- (3,3-DIFLUOROCYCLOBUTOXY) -6-METHYLPYRIDIN-2-YL) ACETAMIDO) PYRIDAZIN-3-YL) -2 -FLUOROBUTYL) -N-METHYL-1H-1,2,3-triazole-4-carboxamide
MX2019002108A (es) 2016-08-25 2019-07-08 Calithera Biosciences Inc Terapia de combinacion con inhibidores de glutaminasa.
EP3503893A4 (en) 2016-08-25 2020-04-29 Calithera Biosciences, Inc. COMBINATION THERAPY WITH GLUTAMINE INHIBITORS
CN107137401A (zh) * 2017-03-28 2017-09-08 刘纪君 一种治疗产后抑郁症的药物组合物
RU2020112558A (ru) 2017-10-18 2021-11-18 Боард Оф Регентс, Зе Юниверсити Оф Тексас Систем Терапия на основе ингибитора глутаминазы
CN114805346A (zh) * 2021-07-08 2022-07-29 成都硕德药业有限公司 杂环类衍生物、其制备方法及用途

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2037257A1 (en) * 1970-07-28 1972-02-03 Farbwerke Hoechst AG, vorm. Meister Lucius & Brüning, 6000 Frankfurt Poly-(5-amino-1,3,4-thiadiazol-2-yl) derivs prepn - intermediates for drug and polymer prodn
US4070400A (en) 1975-10-16 1978-01-24 Merck & Co., Inc. Diphenyl polyamides having a cyclohexylene moiety
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4517288A (en) 1981-01-23 1985-05-14 American Hospital Supply Corp. Solid phase system for ligand assay
CA1291031C (en) 1985-12-23 1991-10-22 Nikolaas C.J. De Jaeger Method for the detection of specific binding agents and their correspondingbindable substances
US4843155A (en) 1987-11-19 1989-06-27 Piotr Chomczynski Product and process for isolating RNA
JPH08508270A (ja) 1993-03-29 1996-09-03 ビーエーエスエフ アクチエンゲゼルシャフト マルチ・ドラッグ耐性のモジュレーターとしての1−アミノ−3−フェノキシ−プロパン誘導体
US5895748A (en) 1996-11-27 1999-04-20 Johnson; Keith R. Panel of antibodies for detecting cadherins and catenins in tissues and method of using the panel of antibodies
EP1087951B9 (en) 1998-06-18 2006-09-13 Bristol-Myers Squibb Company Carbon substituted aminothiazole inhibitors of cyclin dependent kinases
WO2000052204A2 (en) 1999-02-22 2000-09-08 Orntoft Torben F Gene expression in bladder tumors
US20030054985A1 (en) 2000-02-22 2003-03-20 Stuart Aaronson N-cadherin modulated migration, invasion, and metastasis
US6974667B2 (en) 2000-06-14 2005-12-13 Gene Logic, Inc. Gene expression profiles in liver cancer
US6451828B1 (en) * 2000-08-10 2002-09-17 Elan Pharmaceuticals, Inc. Selective inhibition of glutaminase by bis-thiadiazoles
ATE261126T1 (de) 2002-08-01 2004-03-15 Mtm Lab Ag Verfahren für lösung-basierte diagnose
WO2006040569A1 (en) 2004-10-14 2006-04-20 Astex Therapeutics Limited Thiophene amide compounds for use in the treatment or prophylaxis of cancers
US20080182865A1 (en) 2005-03-11 2008-07-31 Witta Samir E Histone deacetylase inhibitors sensitize cancer cells to epidermal growth factor inhibitors
EP1861715B1 (en) 2005-03-16 2010-08-11 OSI Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors
US8716472B2 (en) 2006-10-16 2014-05-06 University Of Rochester Tripodal cyclohexane derivatives and their use as carbohydrate receptors
MX2010005324A (es) 2007-11-19 2010-06-01 Genentech Inc Composiciones y metodos para inhibir el avance del tumor.
WO2009111067A2 (en) 2008-03-07 2009-09-11 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal -like tumor cells or their formation
EP2399129B1 (en) 2009-02-20 2015-11-25 Michael P. Lisanti A method of diagnosis or prognosis of a neoplasm comprising determining the level of expression of a protein in stromal cells adjacent to the neoplasm
US10532034B2 (en) 2009-03-25 2020-01-14 Cornell University Inhibition of glutaminase C
WO2010120966A1 (en) 2009-04-17 2010-10-21 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors
US20130109643A1 (en) * 2010-05-10 2013-05-02 The Johns Hopkins University Metabolic inhibitor against tumors having an idh mutation
ES2638522T3 (es) 2010-06-23 2017-10-23 University Of Louisville Research Foundation, Inc. Procedimientos para detectar cáncer
WO2012006506A1 (en) 2010-07-09 2012-01-12 Massachusetts Institute Of Technology Metabolic gene, enzyme, and flux targets for cancer therapy
UY33930A (es) 2011-03-04 2012-10-31 Novartis Ag Inhibidores novedosos de quinasas
CN102827073A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
WO2013043125A1 (en) * 2011-09-20 2013-03-28 Temasek Life Sciences Laboratory Limited Enterovirus 71 specific antibodies and uses thereof
ES2761866T3 (es) * 2011-11-21 2020-05-21 Calithera Biosciences Inc Inhibidores heterocíclicos de glutaminasa
RU2014141114A (ru) 2012-03-15 2016-05-10 Дзе Рисерч Фаундейшн Фор Дзе Стейт Юниверсити Оф Нью Йорк Комбинированные виды терапии с использованием ингибиторов внеклеточного домена е-кадгерина
BR112015011756A2 (pt) * 2012-11-21 2017-07-11 Agios Pharmaceuticals Inc inibidores da glutamase e métodos de uso
WO2014079011A1 (en) 2012-11-22 2014-05-30 Agios Pharmaceuticals, Inc. Heterocyclic compounds for inhibiting glutaminase and their methods of use
US9029531B2 (en) 2012-11-22 2015-05-12 Agios Pharmaceuticals, Inc. Compounds and their methods of use
WO2014138391A1 (en) 2013-03-06 2014-09-12 The Johns Hopkins University Targeting glutamine metabolism in brain tumors
EA201991183A1 (ru) 2014-01-06 2020-02-28 Ризен Фармасьютикалз Са Новые ингибиторы глутаминазы
CN106231900B (zh) 2014-03-21 2019-05-28 阿吉奥斯制药公司 化合物及其使用方法

Also Published As

Publication number Publication date
JP6333280B2 (ja) 2018-05-30
EP2922832A1 (en) 2015-09-30
US20150299152A1 (en) 2015-10-22
JP2016500107A (ja) 2016-01-07
CN105263915A (zh) 2016-01-20
US20180370930A1 (en) 2018-12-27
AU2013347933A1 (en) 2015-06-11
SG11201504022RA (en) 2015-06-29
AU2013347933A2 (en) 2015-07-09
EA201590997A1 (ru) 2015-11-30
US20140142146A1 (en) 2014-05-22
US10414740B2 (en) 2019-09-17
BR112015011756A2 (pt) 2017-07-11
CN105263915B (zh) 2019-04-12
MX369691B (es) 2019-11-19
AU2013347933B2 (en) 2018-03-29
ES2761951T3 (es) 2020-05-21
MX2015006478A (es) 2015-12-03
WO2014081925A1 (en) 2014-05-30
KR20150085078A (ko) 2015-07-22
EP2922832B1 (en) 2019-10-09
US9303002B2 (en) 2016-04-05
IL238959A (en) 2017-12-31
IL238959A0 (en) 2015-07-30
CA2892089A1 (en) 2014-05-30
AU2018204692A1 (en) 2018-07-19
EA029531B1 (ru) 2018-04-30
US10011574B2 (en) 2018-07-03
AU2013347933C1 (en) 2018-10-04

Similar Documents

Publication Publication Date Title
HK1213889A1 (zh) 殼氨醯胺酶抑制劑及使用方法
HRP20180953T1 (hr) Supstituirani 3-haloalilaminski inhibitori za ssao i njihove uporabe
HK1216248A1 (zh) 纖溶酶原激活物抑制因子- 抑制劑和其使用方法
IL237849B (en) ret suppressors and their uses
EP2678018A4 (en) COMBINATION OF CHINESE HEMMER AND USES THEREOF
EP2895083A4 (en) LIGATOR AND METHOD FOR ITS USE
EP2964651A4 (en) BMP HEMMER AND METHOD OF USE THEREOF
SI2909204T1 (sl) Inhibitorji GSK3 in postopki njihove uporabe
ZA201306188B (en) Mst1 kinase inhibitors and methods of their use
EP2912178A4 (en) SUPER AMPLIFIER AND METHOD FOR USE THEREOF
EP2970311A4 (en) BMP INHIBITORS AND METHODS OF USE
HK1207968A1 (zh) 抑制劑及其使用方法
HK1202112A1 (zh) 端錨聚合酶的吡咯並嘧啶酮和吡咯並吡啶酮抑制劑
ZA201601701B (en) Inhibitors of erk and methods of use
EP2852397A4 (en) HUWENTOXIN IV VARIANTS AND METHODS OF USE
HK1206282A1 (zh) 抑制劑及其使用方法
EP2809662A4 (en) INHIBITORS OF RIBONUCLEOTIDE REDUCTASE AND METHODS OF USE
EP2688901A4 (en) INHIBITORS OF 17SS-HSD1, 17SS-HSD3 AND 17SS-HSD10
HK1205695A1 (zh) 副粘病毒和使用方法